SCHEMBL25354191

SCHEMBL25354191

FC(F)c1nnc(-c2ccc(Cn3cc(-c4cc(C(F)(F)F)cc(C(F)(F)F)c4)nn3)cc2)o1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 5/20 0.55
▸ HSP90AA1 P07900 5/20 0.53
▸ HSP90AB1 P08238 5/20 0.53
▸ TEK Q02763 3/20 0.48
▸ KDR P35968 2/20 0.48
▸ EPHB4 P54760 2/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ GPR55 Q9Y2T6 1/20 0.44
▸ PSEN1 P49768 1/20 0.42
▸ PSEN2 P49810 1/20 0.42
▸ KCNH2 Q12809 1/20 0.42
▸ APH1B Q8WW43 1/20 0.42
▸ NCSTN Q92542 1/20 0.42
▸ APH1A Q96BI3 1/20 0.42
▸ PSENEN Q9NZ42 1/20 0.42
▸ NR1I3 Q14994 1/20 0.41
▸ ESRRG P62508 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22557555 0.91 HDAC6 (0.59) HDAC6HSP90AA1HSP90AB1TEKKDR
SCHEMBL25348490 0.86 HSP90AA1 (0.44) HDAC6HSP90AA1HSP90AB1TEKKDR
SCHEMBL25992735 0.85 HDAC6 (0.57) HDAC6HSP90AA1HSP90AB1TEKKDR
SCHEMBL22558008 0.83 HDAC6 (0.62) HDAC6HSP90AA1HSP90AB1TEKKDR
SCHEMBL24215835 0.83 HDAC6 (0.62) HDAC6TEKKDREPHB4MEN1
SCHEMBL25350331 0.83 HDAC6 (0.57) HDAC6TEKKDREPHB4ESRRG
SCHEMBL25244262 0.82 HDAC6 (0.61) HDAC6HSP90AA1HSP90AB1TEKKDR
SCHEMBL24599266 0.82 HDAC6 (0.61) HDAC6HSP90AA1HSP90AB1TEKKDR
SCHEMBL25386563 0.81 HDAC6 (0.60) HDAC6HSP90AA1HSP90AB1TEKKDR
SCHEMBL24216740 0.81 HDAC6 (0.55) HDAC6TEKKDREPHB4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116157398-B Oxadiazole-based selective histone deacetylase 6 inhibitors 意大发马克股份公司 2025-03-11 — — CN claimed
US-20230257372-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-08-17 — — US disclosed
US-20230257372-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-08-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257372-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HDAC6, HDAC1, HDAC3 HDAC6 1/4885HSP90AA1 153/4885HSP90AB1 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback